The Centre of Excellence Redefining Radiotherapy
In May 2026, a new Centre of Excellence began a phased rollout that will make Australia the first country to house the three leading precision-radiation technologies under one roof. The partnership between Icon Cancer Centre Australia and Macquarie University Health will bring Gamma Knife, CyberKnife, and advanced linear accelerator technology together in a single facility, offering highly targeted, less-invasive radiotherapy that can treat tumours with sub-millimetre accuracy.
Mark Middleton, CEO of Icon Group, described the significance bluntly: “This centre represents the next chapter in Australia’s stereotactic capability. By bringing Gamma Knife, CyberKnife, and advanced linac technology together under one roof, we’re creating a nationally-significant hub for precision medicine, paving the future of cancer care”.
Around 50 percent of all cancer patients require radiation oncology as part of their treatment. The ability to deliver radiation with sub-millimetre precision reduces side effects, shortens treatment times, and decreases the travel burden for patients and their families. For patients in New South Wales and beyond, the Centre represents a genuine leap forward in accessible, world-class cancer care.
Robotic Bronchoscopy and the Fight Against Lung Cancer
At Epworth in Victoria, a different kind of precision technology is transforming lung cancer diagnosis. The Ion robotic bronchoscopy platform, which Epworth operates as the only hospital in Victoria with this technology, allows clinicians to navigate through a complex maze of airways to reach peripheral lung nodules that were previously difficult to access. In late 2025, Epworth also launched one of Australia’s first Priority Lung Screening Assessment Services, combining advanced diagnostics with a systematic approach to early detection.
The robotic platform represents a significant improvement over conventional bronchoscopy, which struggles to reach distant lung lesions. By enabling earlier and more accurate diagnosis, it increases the likelihood that lung cancer is caught at a stage when curative treatment is possible.
AI-Powered Diagnostics Across Multiple Fronts
The precision revolution extends beyond radiation and robotics. In Western Australia, an AI-powered retinal screening tool called Ninox Vision is being offered free to GP practices for a one-year trial. The technology allows a health assistant or receptionist to photograph a patient’s retina in minutes, with an AI-generated diagnosis delivered instantly to the GP’s electronic medical record.
At Northern Health in Victoria, an Australian-first study is evaluating AISAP, an AI-assisted point-of-care ultrasound platform designed to transform how cardiac conditions are diagnosed at the bedside. The secure, cloud-based platform uses advanced artificial intelligence to support clinicians in acquiring and interpreting cardiac ultrasound images.
In cancer diagnostics, researchers at QIMR Berghofer Medical Research Institute have developed an AI screening tool called STimage that uses spatial biology analysis to accurately predict breast cancer outcomes. Meanwhile, a new AI-powered trial led by Associate Professor Narinder Singh at Westmead Private Hospital is using artificial intelligence to analyse images of children’s eardrums, providing immediate assessment of whether disease is present. The DrumBeat.ai trial is underway in remote regions of Western Australia, targeting a condition that disproportionately affects Aboriginal children.
The Common Thread: Precision at Scale
What unites these developments is a shared commitment to precision: treating the right patient with the right intervention at the right time. Whether through stereotactic radiotherapy that spares healthy tissue, robotic bronchoscopy that reaches previously inaccessible nodules, or AI diagnostics that bring specialist-level analysis to primary care settings, Australian specialist clinics are systematically reducing the gap between what is technologically possible and what is routinely available.
The Centre of Excellence’s phased rollout, with full stereotactic capabilities becoming available over the course of 2026, reflects a pragmatic approach to innovation: integrate new technologies carefully, support clinical teams through the transition, and maintain a focus on safety and quality throughout.
For patients, the cumulative effect is significant. Earlier diagnosis, more targeted treatment, and fewer side effects are not abstract promises but measurable outcomes already being delivered in clinics across the country.
